Success Metrics

Clinical Success Rate
50.0%

Based on 1 completed trials

Completion Rate
50%(1/2)
Active Trials
0(0%)
Results Posted
100%(1 trials)
Terminated
1(33%)

Phase Distribution

Ph not_applicable
1
33%
Ph phase_3
2
67%

Phase Distribution

0

Early Stage

0

Mid Stage

2

Late Stage

Phase Distribution3 total trials
Phase 3Large-scale testing
2(66.7%)
N/ANon-phased studies
1(33.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

50.0%

1 of 2 finished

Non-Completion Rate

50.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

3

all time

Status Distribution
Completed(1)
Terminated(1)
Other(1)

Detailed Status

Terminated1
Completed1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
0
Success Rate
50.0%
Most Advanced
Phase 3

Trials by Phase

Phase 32 (66.7%)
N/A1 (33.3%)

Trials by Status

terminated133%
completed133%
unknown133%

Recent Activity

0 active trials
Showing 3 of 3
unknownnot_applicable

Application of Vascular Closure Device in Transvenous Cardiac Intervention

NCT05521100
terminatedphase_3

Effectiveness and Safety Confirmation Between FASTSEAL® Bioabsorbable VCD and Perclose® ProGlide SMC System

NCT01597570
completedphase_3

Safety and Effectiveness Study of the Ensure Medical Vascular Closure Device

NCT00345631

Clinical Trials (3)

Showing 3 of 3 trials
NCT05521100Not Applicable

Application of Vascular Closure Device in Transvenous Cardiac Intervention

Unknown
NCT01597570Phase 3

Effectiveness and Safety Confirmation Between FASTSEAL® Bioabsorbable VCD and Perclose® ProGlide SMC System

Terminated
NCT00345631Phase 3

Safety and Effectiveness Study of the Ensure Medical Vascular Closure Device

Completed

All 3 trials loaded

Drug Details

Intervention Type
DEVICE
Total Trials
3